- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- 23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 20
- States / cities
- Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 5,391
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
- Interventions
- Tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Thrombotic Microangiopathy
- Interventions
- Ravulizumab, Best Supportive Care
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Advanced Cancer
- Interventions
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Drug
- Lead sponsor
- Riboscience, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- ZD6474 (vandetanib), Best Supportive Care
- Drug · Other
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Germantown, Tennessee
- Conditions
- Heart Failure
- Interventions
- Baxdrostat and dapagliflozin, Placebo and dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Interventions
- SB-509, Saline
- Drug · Other
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
- Conditions
- Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
- Interventions
- Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 288
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-561, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
- Drug · Procedure
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 48
- States / cities
- Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
- Interventions
- Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
- Conditions
- Sleep Initiation and Maintenance Disorders, Insomnia
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Nocturia
- Interventions
- VA106483
- Drug
- Lead sponsor
- Vantia Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
- Conditions
- Health-related Quality of Life
- Interventions
- Vitality Product, Placebo
- Dietary Supplement
- Lead sponsor
- Pharmanex
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Chaska, Minnesota • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide(Nubeqa, BAY1841788)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 24
- States / cities
- Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more
- Conditions
- Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture
- Interventions
- 10% povidone-iodine (1% free iodine) in purified water, 4% chlorhexidine gluconate (CHG) in purified water
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 8 more
- Conditions
- Constipation
- Interventions
- N-methylnaltrexone bromide (MOA-728), placebo
- Drug · Other
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Interventions
- rituximab, ABT-263
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
- Conditions
- Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
- Interventions
- Hello (serious game), The Conversation Project (CP) Starter Kit, Table Topics (general conversation game)
- Behavioral · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 79
- States / cities
- Athens, Alabama • Kingman, Arizona • Show Low, Arizona + 70 more
- Conditions
- Recurrent Pericarditis
- Interventions
- Not listed
- Lead sponsor
- Kiniksa Pharmaceuticals International, plc
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 29
- States / cities
- Anchorage, Alaska • Tucson, Arizona • La Jolla, California + 23 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Osteoarthritis, Hip
- Interventions
- Synvisc-One (hylan G-F 20), Placebo
- Device
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 45
- States / cities
- Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 53
- States / cities
- Pell City, Alabama • Tucson, Arizona • Fountain Valley, California + 49 more
- Conditions
- Pancreatic Cancer
- Interventions
- TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Bakersfield, California + 25 more